Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells

KIZ OpenIR > 分子病理学

	Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells
	Lin WM 1,4; Karsten U 2; Goletz S 2; Cheng RC 3; Cao Y*1; caoy@mail.kiz.ac.cn
	2010
发表期刊	VIRCHOWS ARCHIV
ISSN	0945-6317
卷号	456 期号:4 页码:403-409
合作性质	其它
摘要	Histo-blood group antigens CD173 (H2) and CD174 (Lewis Y) are known to be developmentally regulated carbohydrate antigens which are expressed to a varying degree on many human carcinomas. We hypothesized that they might represent markers of cancer-initiating cells (or cancer stem cells, CSC). In order to test this hypothesis, we examined the co-expression of CD173 and CD174 with stem cell markers CD44 and CD133 by flow cytometry analysis, immunocytochemistry, and immunohistochemistry on cell lines and tissue sections from breast cancer. In three breast cancer cell lines, the percentage of CD173(+)/CD44(+) cells ranged from 17% to > 60% and of CD174(+)/CD44(+) from 21% to 57%. In breast cancer tissue sections from 15 patients, up to 50% of tumor cells simultaneously expressed CD173, CD174, and CD44 antigens. Co-expression of CD173 and CD174 with CD133 was also observed, but to a lesser percentage. Co-immunoprecipitation and sandwich ELISA experiments on breast cancer cell lines suggested that CD173 and CD174 are carried on the CD44 molecule. The results show that in these tissues CD173 (H2) and CD174 (LeY) are associated with CD44 expression, suggesting that these carbohydrate antigens are markers of cancer-initiating cells or of early progenitors of breast carcinomas.
关键词	Breast Cancer-initiating Cells Co-expression Cd44 Cd173 (H2) Cd174 (Ley)
资助者	This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15).
收录类别	SCI
资助者	This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15). ; This research was supported by a grant from Yunnan Province Science and Technology Department (2008CCO15).
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/3377
专题	分子病理学科研部门_动物模型与人类重大疾病机理重点实验室
通讯作者	caoy@mail.kiz.ac.cn
作者单位	1.Laboratory of Molecular and Experimental Pathology, Key Laboratory of Animal Models and Human Disease Mechanisms of CAS and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, 32 Jiaochang Donglu, Kunming, Yunnan 650223, China 2.Glycotope GmbH, Berlin-Buch, Germany 3.Department of General Surgery, First Affiliated Hospital of Kunming Medical College, Kunming, China 4.College of Life Sciences, Longyan University, Longyan, China
推荐引用方式 GB/T 7714	Lin WM,Karsten U,Goletz S,et al. Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells[J]. VIRCHOWS ARCHIV,2010,456(4):403-409.
APA	Lin WM,Karsten U,Goletz S,Cheng RC,Cao Y*,&caoy@mail.kiz.ac.cn.(2010).Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells.VIRCHOWS ARCHIV,456(4),403-409.
MLA	Lin WM,et al."Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells".VIRCHOWS ARCHIV 456.4(2010):403-409.

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2010456403.pdf（226KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文